Working… Menu

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02869243
Recruitment Status : Active, not recruiting
First Posted : August 16, 2016
Last Update Posted : November 19, 2020
ORION Clinical Services
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : October 16, 2020
Estimated Study Completion Date : March 31, 2021